These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
508 related articles for article (PubMed ID: 31241775)
1. Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer. Ma F; Guan Y; Yi Z; Chang L; Li Q; Chen S; Zhu W; Guan X; Li C; Qian H; Xia X; Yang L; Zhang J; Husain H; Liao Z; Futreal A; Huang J; Yi X; Xu B Int J Cancer; 2020 Mar; 146(5):1359-1368. PubMed ID: 31241775 [TBL] [Abstract][Full Text] [Related]
2. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy. Ma F; Zhu W; Guan Y; Yang L; Xia X; Chen S; Li Q; Guan X; Yi Z; Qian H; Yi X; Xu B Oncotarget; 2016 Oct; 7(40):66020-66031. PubMed ID: 27602761 [TBL] [Abstract][Full Text] [Related]
3. Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis. Lin Y; Lin M; Zhang J; Wang B; Tao Z; Du Y; Zhang S; Cao J; Wang L; Hu X Cancer Res Treat; 2020 Oct; 52(4):1059-1066. PubMed ID: 32340083 [TBL] [Abstract][Full Text] [Related]
4. Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial. Hrebien S; Citi V; Garcia-Murillas I; Cutts R; Fenwick K; Kozarewa I; McEwen R; Ratnayake J; Maudsley R; Carr TH; de Bruin EC; Schiavon G; Oliveira M; Turner N Ann Oncol; 2019 Jun; 30(6):945-952. PubMed ID: 30860573 [TBL] [Abstract][Full Text] [Related]
5. High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2- postmenopausal breast cancer patients treated with everolimus and exemestane. Kruger DT; Jansen MPHM; Konings IRHM; Dercksen WM; Jager A; Oulad Hadj J; Sleijfer S; Martens JWM; Boven E Mol Oncol; 2020 Mar; 14(3):490-503. PubMed ID: 31841262 [TBL] [Abstract][Full Text] [Related]
6. Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance. Hu ZY; Xie N; Tian C; Yang X; Liu L; Li J; Xiao H; Wu H; Lu J; Gao J; Hu X; Cao M; Shui Z; Xiao M; Tang Y; He Q; Chang L; Xia X; Yi X; Liao Q; Ouyang Q EBioMedicine; 2018 Jun; 32():111-118. PubMed ID: 29807833 [TBL] [Abstract][Full Text] [Related]
7. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525 [TBL] [Abstract][Full Text] [Related]
8. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer. Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242 [TBL] [Abstract][Full Text] [Related]
9. The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer. Jacob S; Davis AA; Gerratana L; Velimirovic M; Shah AN; Wehbe F; Katam N; Zhang Q; Flaum L; Siziopikou KP; Platanias LC; Gradishar WJ; Behdad A; Bardia A; Cristofanilli M Clin Cancer Res; 2021 Mar; 27(5):1361-1370. PubMed ID: 33323406 [TBL] [Abstract][Full Text] [Related]
10. Association of emergence of new mutations in circulating tumuor DNA during chemotherapy with clinical outcome in metastatic colorectal cancer. Jia N; Chang L; Gao X; Shi X; Dou X; Guan M; Shao Y; Li N; Cheng Y; Ying H; Sun Z; Zhou Y; Zhao L; Zhou J; Bai C BMC Cancer; 2021 Jul; 21(1):845. PubMed ID: 34294055 [TBL] [Abstract][Full Text] [Related]
11. Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial. Rothé F; Silva MJ; Venet D; Campbell C; Bradburry I; Rouas G; de Azambuja E; Maetens M; Fumagalli D; Rodrik-Outmezguine V; Di Cosimo S; Rosa D; Chia S; Wardley A; Ueno T; Janni W; Huober J; Baselga J; Piccart M; Loi S; Sotiriou C; Dawson SJ; Ignatiadis M Clin Cancer Res; 2019 Jun; 25(12):3581-3588. PubMed ID: 30862692 [TBL] [Abstract][Full Text] [Related]
12. Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer. Shibayama T; Low SK; Ono M; Kobayashi T; Kobayashi K; Fukada I; Ito Y; Ueno T; Ohno S; Nakamura Y; Takahashi S Breast Cancer Res Treat; 2020 Apr; 180(2):331-341. PubMed ID: 32020432 [TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic Characteristics of HER2-positive Metastatic Colorectal Cancer and Detection of HER2 in Plasma Circulating Tumor DNA. Wei Q; Zhang Y; Gao J; Li J; Li J; Li Y; Zhou J; Lu M; Gong J; Zhang X; Shen L; Sun Y; Chang L; Wang X Clin Colorectal Cancer; 2019 Sep; 18(3):175-182. PubMed ID: 31227437 [TBL] [Abstract][Full Text] [Related]
14. Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients. Darrigues L; Pierga JY; Bernard-Tessier A; Bièche I; Silveira AB; Michel M; Loirat D; Cottu P; Cabel L; Dubot C; Geiss R; Ricci F; Vincent-Salomon A; Proudhon C; Bidard FC Breast Cancer Res; 2021 Mar; 23(1):31. PubMed ID: 33676547 [TBL] [Abstract][Full Text] [Related]
15. Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer. Guan X; Liu B; Niu Y; Dong X; Zhu X; Li C; Li L; Yi Z; Sun X; Chen H; Lu S; Ma F Breast; 2020 Feb; 49():261-266. PubMed ID: 31927339 [TBL] [Abstract][Full Text] [Related]
16. Circulating tumor DNA analyses predict progressive disease and indicate trastuzumab-resistant mechanism in advanced gastric cancer. Wang Y; Zhao C; Chang L; Jia R; Liu R; Zhang Y; Gao X; Li J; Chen R; Xia X; Bulbul A; Husain H; Guan Y; Yi X; Xu J EBioMedicine; 2019 May; 43():261-269. PubMed ID: 31031019 [TBL] [Abstract][Full Text] [Related]
17. The molecular tumor burden index as a response evaluation criterion in breast cancer. Yi Z; Ma F; Rong G; Liu B; Guan Y; Li J; Sun X; Wang W; Guan X; Mo H; Wang J; Qian H; Xu B Signal Transduct Target Ther; 2021 Jul; 6(1):251. PubMed ID: 34230452 [TBL] [Abstract][Full Text] [Related]
18. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer. Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078 [TBL] [Abstract][Full Text] [Related]
19. Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling. Chen Z; Sun T; Yang Z; Zheng Y; Yu R; Wu X; Yan J; Shao YW; Shao X; Cao W; Wang X Mol Genet Genomic Med; 2020 Feb; 8(2):e1079. PubMed ID: 31867841 [TBL] [Abstract][Full Text] [Related]
20. Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. Parikh AR; Mojtahed A; Schneider JL; Kanter K; Van Seventer EE; Fetter IJ; Thabet A; Fish MG; Teshome B; Fosbenner K; Nadres B; Shahzade HA; Allen JN; Blaszkowsky LS; Ryan DP; Giantonio B; Goyal L; Nipp RD; Roeland E; Weekes CD; Wo JY; Zhu AX; Dias-Santagata D; Iafrate AJ; Lennerz JK; Hong TS; Siravegna G; Horick N; Clark JW; Corcoran RB Clin Cancer Res; 2020 Apr; 26(8):1877-1885. PubMed ID: 31941831 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]